Cytopia zeroes in on brain
Monday, 17 November, 2008
Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.
The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.
CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.
The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
